Hypocalcemia is the occurs when serum calcium concentration is below the lower limit of normal range.
Acute hypocalcemia has neuromuscular tetany as hallmark symptom. Patients have rapid decrease in serum calcium and present with symptomatic hypocalcemia.
It is an emergency condition and requires immediate attention. Ca (IV) should be administered until signs and symptoms abate or until serum Ca levels rise.
Chronic hypocalcemia has asymptomatic mild hypocalcemia. Treatment is necessary to avoid long term complications. Oral Ca may be administered.
The incidence of denosumab-related hypocalcaemia in postmenopausal women with osteoporosis appears to be higher in real-life clinical settings than what is reported in clinical trials. However, a protocol that requires assessment and replacement of vitamin D, calcium and creatinine levels in all patients prescribed denosumab lowers the incidence, according to a study presented at the 6th Asia-Pacific Osteoporosis Meeting (IOF Regionals 2016) in Singapore.
Loaded calcitriol therapy manages hypocalcaemia in the first 7 days after parathyroidectomy for chronic kidney diseases compared with titrated calcitriol and control, as shown in a randomised control, open labeled study.
In this article, the path of hypocalcemia during the first days of critical illness was established in terms of mortality. The role of calcium supplementation on calcium normalization and mortality was assessed as well.
Asia's trusted medical magazine for healthcare professionals.
Get your MIMS Endocrinology - Malaysia digital copy today!
New drug applications approved by US FDA as of 1 - 15 December 2016 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
The American Diabetes Association’s (ADA) President Desmond Schatz challenged the scientific community to transform diabetes from an invisible disease to a highly visible crisis. “Diabetes is an epidemic spiralling out of control across this country and around the world, yet it remains largely invisible,” he said, speaking at the 76th Scientific Sessions of ADA in New Orleans, Louisiana, US.
New drug applications approved by US FDA as of 16 - 31 July 2017 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.